{"product_id":"perrigo-pestle-analysis","title":"Perrigo Company PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain a strategic edge with our concise PESTLE snapshot for Perrigo Company: it reveals how regulation, macroeconomics, and technological shifts shape growth and risks. Perfect for investors and strategists, the full PESTLE delivers deeper, actionable insights. Purchase the complete report to access the detailed analysis now.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOTC regulatory agendas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernment priorities on self-care and OTC access drive category growth—US OTC retail sales were roughly $40 billion in 2024—shaping approval timelines and Rx-to-OTC switches that affect Perrigo’s ~3.2 billion USD annual revenue profile. FDA monograph reform remains in active rulemaking with hundreds of stakeholder comments, while EMA, MHRA and TGA updates since 2023 have tightened some claim pathways and relaxed others. Perrigo must engage policy consultations to influence standards and budget for compliance investments, and divergent national policies force adaptive labeling and portfolio strategies across markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug pricing and affordability politics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolitical pressure to curb healthcare costs pushes consumers toward OTC and private-label solutions, which supports Perrigo’s value positioning. However, retailer margin compression and reference-pricing initiatives can squeeze manufacturers during negotiations under public scrutiny. HSA\/FSA policy influences self-care spending—2024 HSA limits were $4,150 individual\/$8,300 family and FSA limit $3,050—shaping consumer willingness to pay.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade policy and tariffs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTariffs on APIs, packaging or finished goods raise Perrigo’s COGS and pricing across US–EU–Australia lanes, given its Ireland headquarters and major manufacturing in the US and Ireland; many industry APIs are sourced from India and China. Post-Brexit regulatory divergence has added customs and compliance friction for UK\/EU movements. Trade tensions with API source countries drive supply reconfiguration, so Perrigo needs tariff engineering and dual-sourcing to mitigate volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic health priorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment vaccination drives, cold\/flu preparedness and self-care literacy programs can lift OTC demand; the global OTC market was about 152.5 billion USD in 2023, offering scale for Perrigo to capture share. Policy shifts in opioid stewardship and revised pain-management guidelines are reshaping analgesic volumes, while pandemic readiness and essential-designation rules drive stockpiling and channel prioritization. Aligning SKUs with public-health messaging enhances credibility and uptake.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eVaccination \u0026amp; preparedness broaden OTC demand\u003c\/li\u003e\n\u003cli\u003eOpioid policies compress analgesic segments\u003c\/li\u003e\n\u003cli\u003ePandemic readiness raises stockpiling\/essential status\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical stability and logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGeopolitical conflicts and sanctions continue to disrupt freight lanes, increase carrier insurance and delay key API and packaging deliveries, pressuring Perrigo supply chains and working capital. European energy policy shocks since 2022 have raised manufacturing input cost volatility and prompted capacity curtailments that affect lead times. Political unrest complicates regulatory inspections and product launches, driving Perrigo to build regional redundancy to limit exposure to single-source disruptions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupply disruption: freight lanes, insurance, delayed APIs\u003c\/li\u003e\n\u003cli\u003eEnergy shocks: higher input cost volatility in Europe\u003c\/li\u003e\n\u003cli\u003eRegulatory risk: inspections and product release delays\u003c\/li\u003e\n\u003cli\u003eMitigation: regional redundancy to reduce localized exposure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory shifts, tariffs and HSA caps reshape OTC market and \u003cstrong\u003e$3.2B\u003c\/strong\u003e exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePerrigo faces regulatory shifts (FDA monograph reform; EMA\/MHRA updates) altering OTC approvals and Rx‑to‑OTC switches, affecting ~3.2bn USD revenue. Tariffs, trade tensions and post‑Brexit friction raise COGS and logistics risk, driving dual‑sourcing. Public cost‑containment and 2024 HSA\/FSA limits ($4,150\/$8,300) push consumers to private‑label OTC.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003e2023–25 Data\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS OTC sales\u003c\/td\u003e\n\u003ctd\u003e$40B (2024)\u003c\/td\u003e\n\u003ctd\u003eMarket growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal OTC\u003c\/td\u003e\n\u003ctd\u003e$152.5B (2023)\u003c\/td\u003e\n\u003ctd\u003eScale opportunity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePerrigo rev\u003c\/td\u003e\n\u003ctd\u003e$3.2B\u003c\/td\u003e\n\u003ctd\u003eRevenue exposure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Perrigo across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends, actionable insights, and forward-looking implications to help executives, investors, and strategists identify risks, opportunities, and scenario-ready strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003ePerrigo Company PESTLE analysis distilled into a concise, shareable brief that quickly highlights regulatory, economic, social and technological risks and opportunities, easing strategic discussions and decision-making across teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer spending and inflation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSticky inflation remaining above 3% in 2024 lifted staple price points and accelerated trade-down to private label, benefiting Perrigo given its scale in store-brand OTCs. Real wage stagnation in 2023–24 increased elasticity across cough\/cold, allergy and digestive categories, shifting consumers toward lower-price tiers. Cyclical input costs for excipients and packaging continued to pressure gross margins. Strategic pack-price architecture and layered value tiers help defend volume.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetailer consolidation dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge US and EU retailers and pharmacy chains (Walmart, Kroger, CVS, Walgreens, Amazon) command roughly half of U.S. grocery\/OTC shelf space, exerting pricing and assortment control. Private-label penetration rose to about 19% in the U.S. in 2024 and tops 30% in some EU categories, boosting Perrigo’s contract-manufacturing volumes but tightening gross margins by roughly 200–300 basis points from promotions and slotting. Strategic joint business planning can secure category captaincy, shelf allocation and promotional funding.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFX and interest rate environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFX swings (USD\/EUR ~1.08, USD\/GBP ~1.27, USD\/AUD ~0.65 mid-2025) materially affect Perrigo’s translated revenues and global input costs. Higher policy rates (Fed ~5.25–5.5%, ECB ~4.0%, BoE ~5.25%) lift working-capital and inventory carrying costs by ~100–200bps in seasonal categories. Hedging policies and natural operational offsets have reduced FX\/rate earnings volatility. Capex timing should follow rate trajectories and higher ROI thresholds.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply chain resilience costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePerrigo’s shift to safety stocks, nearshoring and dual-sourcing raises service levels but lifts inventory and overheads; inventory carrying can increase months of working capital. Ocean freight fell roughly 60% from 2022 peaks to 2024 (Drewry) while air rates in 2024 remained about 30–40% above 2019 (IATA), driving landed-cost variance. API availability and 6–12 month qualification lead times delay NPI calendars; APICS studies show planning and VMI can cut bullwhip variance 20–40%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSafety stocks: higher working capital\u003c\/li\u003e\n\u003cli\u003eNearshoring\/dual-sourcing: up-front capex\/overhead\u003c\/li\u003e\n\u003cli\u003eFreight cycles: ocean -60% vs 2022; air +30–40% vs 2019\u003c\/li\u003e\n\u003cli\u003eAPI lead times: 6–12 months\u003c\/li\u003e\n\u003cli\u003eAdvanced planning\/VMI: reduce variability 20–40%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCategory seasonality and epidemiology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCold and flu intensity drives volatile week-to-week demand spikes for Perrigo cough\/cold SKUs, with US influenza activity peaking in Dec 2023–Jan 2024 per CDC surveillance, amplifying OTC sell-through and inventory churn. Climate-driven shifts have lengthened allergy seasons, changing sell-in timing and return rates for antihistamines and nasal products. Economic cycles push consumers between efficacy-focused generics and premium wellness SKUs; Perrigo’s flexible manufacturing and rapid changeovers capture upside during spikes.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSeasonal peaks: CDC Dec 2023–Jan 2024\u003c\/li\u003e\n\u003cli\u003eAllergy lengthening: climate-driven shifts\u003c\/li\u003e\n\u003cli\u003eBasket shift: value vs premium in recessions\u003c\/li\u003e\n\u003cli\u003eOperational edge: fast changeovers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory shifts, tariffs and HSA caps reshape OTC market and \u003cstrong\u003e$3.2B\u003c\/strong\u003e exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSticky inflation \u0026gt;3% in 2024 raised staple prices and accelerated private‑label share; US private‑label ~19% (2024). FX mid‑2025 USD\/EUR ~1.08 and policy rates (Fed 5.25–5.5%) lift carry costs; hedging mitigates volatility. Freight: ocean -60% vs 2022, air +30–40% vs 2019; API lead times 6–12 months, pressuring NPI timing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInflation (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS private‑label (2024)\u003c\/td\u003e\n\u003ctd\u003e~19%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSD\/EUR (mid‑2025)\u003c\/td\u003e\n\u003ctd\u003e~1.08\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed rate\u003c\/td\u003e\n\u003ctd\u003e5.25–5.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOcean freight vs 2022\u003c\/td\u003e\n\u003ctd\u003e-60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAir freight vs 2019\u003c\/td\u003e\n\u003ctd\u003e+30–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI lead times\u003c\/td\u003e\n\u003ctd\u003e6–12 mo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003ePerrigo Company PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThis Perrigo Company PESTLE Analysis offers a concise, professionally structured review of political, economic, social, technological, legal, and environmental factors affecting the business. The preview shown here is the exact document you’ll receive after purchase—fully formatted and ready to use. No placeholders or teasers: what you see is the final file available for immediate download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55675418739065,"sku":"perrigo-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/perrigo-pestle-analysis.png?v=1755808012","url":"https:\/\/portersfiveforce.com\/products\/perrigo-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}